Please assess the completion status of the following clinical trial:

Trial Title: A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 to 75 years of age~* Advanced and/or metastatic gastric cancer with at least 1 measurable lesion~Exclusion Criteria:~* Uncontrolled infection~* Evidence of central nervous system (CNS) metastases~* History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix~* Radiation therapy or major surgery within 4 weeks of study drug~* Previous chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 5-Fluorouracil + Cisplatin (Type: ACTIVE_COMPARATOR): Participants will receive 5-FU in combination with cisplatin upto disease progression.
- Capecitabine + Cisplatin (Type: EXPERIMENTAL): Participants will receive capecitabine in combination with cisplatin upto disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).